Maxigen Biotech Inc. 1783.TW Stock

Maxigen Biotech Inc. researches, develops, produces, and sells implantable medical device and cosmetic products in Taiwan, the United States, Europe, rest of Asia, and internationally. It operates in two segments, Biomedical Products and Consumer Products. The company offers intra-articular injections under the ArtiAid, ArtiAid Plus, and ArtiBest names to treat osteoarthritis; Foramic, a bone substitute granule; FormaGraft, a bone graft substitute; GingivAid, a collagen dental grafts for use in dental implant surgery; BestAid, a collagen bone graft; FormaSetin, an injectable bone void filler; and MaxiBone, a calcium phosphate ceramic. It also provides FormaAid, a guided tissue regeneration membrane; HealiAid, a collagen wound dressing product for dental and surgical use; dermal filler injections under the Formaderm brand; and ophthalmic viscoelastic device under the ViscAid, PreviscAid, and BiVisc names. In addition, the company offers cosmetic products, which include face wash, make-up remover, toners, serums, lotions, day creams, night creams, eye creams, raw serums, sunscreen, sunscreen lotion, essential care, moisturizing, whitening, anti-wrinkle, antiallergy, efficacy care, bathing, exfoliating, breast and buttock slimming, shampoo, conditioner, and hair spray products, as well as non-woven, crystal, VT, compression, and bio-fiber face masks. Maxigen Biotech Inc. was incorporated in 1998 and is headquartered in Taoyuan City, Taiwan.